Cheryl Guttman Krader, BS, Pharm

Articles by Cheryl Guttman Krader, BS, Pharm

The prevalence of non-adherence with IOP-lowering medications underscores the need for optometrists to frequently re-assess medication use in glaucoma patients and consider therapies that will enable compliance and prevent it from becoming an efficacy-limiting issue.

Analyses of visual acuity results from phase III clinical trials investigating Q.D. bromfenac sodium ophthalmic solution 0.09% for treatment of inflammation and reduction of pain after cataract surgery show treatment with this nonsteroidal anti-inflammatory drug provides functional benefits in addition to its anti-inflammatory and analgesic effects.

A post hoc analysis of data collected in two published, pivotal clinical trials demonstrates that in addition to its efficacy for treating inflammation following ocular surgery, loteprednol etabonate ophthalmic suspension 0.5% provides statistically significant relief of postoperative pain and other symptoms.

Latest Updated Articles